Dolby Laboratories (NYSE:DLB) Bolsa

DOLBY LABORATORIES INC-CL A

Dolby Laboratories

Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.

AMCNew,York,,Usa,-,September,14,,2023:,Amc,Sign,Near

News

Movers

AMC ampliará Dolby Cinema en EE.UU., pero sus acciones bajan un 2,13 %. ¿Cómo afectará esto a su futuro en la industria?

AMC expande Dolby Cinema, pero sus acciones caen

AAPL

AKAM

AVGO

DOCU

ENPH

FSLR

GOOG

GOOGL

TSLA

Acciones tecnológicas con valoraciones atractivas y gran potencial de crecimiento. Desde energía renovable hasta TI, descubre dónde invertir.

Acciones tecnológicas con valoraciones atractivas en 2025: ¿Dónde invertir con menor riesgo?

Dolby Laboratories Inc

4 analysts have expressed a variety of opinions on Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Dolby Laboratories, revealing an average target of $100.5, a high estimate of $112.00, and a low estimate of $95.00. A decline of 2.19% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1749816098_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Dolby Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Frankel</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Lowers</td>
<td>Buy</td>
<td>$112.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Patrick Sholl</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Frankel</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dolby Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dolby Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dolby Laboratories's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dolby Laboratories analyst ratings.</a>
<h2>Unveiling the Story Behind Dolby Laboratories</h2>
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company designs and manufactures audio, imaging, accessibility, and other hardware and software solutions for the cinema, with occasional applications in the television, broadcast, and live entertainment industries. The company operates in the United States and internationally.
<h3>Key Indicators: Dolby Laboratories's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Dolby Laboratories's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 1.38%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Dolby Laboratories's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.84%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Dolby Laboratories's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 3.61%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Dolby Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.87% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dolby Laboratories's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Dolby Laboratories Stock: Analyst Perspectives (4 Ratings)

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $95 price target.

Price Target

Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $95 Price Target

Tigress Financial analyst Ivan Feinseth maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and lowers the price target from $116 to $112.

Tigress Financial Maintains Buy on Dolby Laboratories, Lowers Price Target to $112

Barrington Research analyst Patrick Sholl maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Outperform and maintains $100 price target.

Barrington Research Maintains Outperform on Dolby Laboratories, Maintains $100 Price Target

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and lowers the price target from $100 to $95.

Rosenblatt Maintains Buy on Dolby Laboratories, Lowers Price Target to $95

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) lowers FY2025 GAAP EPS guidance from $2.39-$2.54 to $2.31-$2.46 vs $2.44 analyst estimate..

Guidance

Dolby Laboratories Lowers FY2025 GAAP EPS Guidance from $2.39-$2.54 to $2.31-$2.46 vs $2.44 Est

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) lowers FY2025 Adj EPS guidance from $3.99-$4.14 to $3.88-$4.03 vs $4.04 analyst estimate. Lowers FY2025 sales outlook from $1.33 billion-$1.39 billion to $1.31 billion-$1.38 billion vs $1.35 billion estimate.

Dolby Laboratories Lowers FY2025 Adj EPS Guidance from $3.99-$4.14 to $3.88-$4.03 vs $4.04 Est; Lowers FY2025 Sales Guidance from $1.33B-$1.39B to $1.31B-$1.38B vs $1.35B Est

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) is looking for Q3 GAAP EPS of $0.26-$0.41 vs $0.46 analyst estimate..

Dolby Laboratories Sees Q3 GAAP EPS $0.26-$0.41 vs $0.46 Est

Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) is looking for Q3 Adj EPS of $0.62-$0.77 vs $0.81 analyst estimate. sees sales of $290.000 million-$320.000 million vs $307.09 million analyst estimate.

Dolby Laboratories Sees Q3 Adj EPS $0.62-$0.77 vs $0.81 Est; Sees Sales $290.000M-$320.000M vs $307.09M Est

Earnings

Earnings Beats

Earnings Misses

Dolby Laboratories Q2 Adj. EPS $1.34 Beats $1.27 Estimate, Sales $369.56M Miss $376.38M Estimate

AAMI

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

WIIM

ADEA

AEIS

AEVA

AGYS

AIOT

ALAB

ALAR

ALGM

AMPG

AMPL

ARLO

ASGN

ASTI

ATOM

BASE

BELFA

BELFB

BIGC

BLBX

BLZE

BTCT

BZAI

CAMT

CCCS

CCRD

CEVA

CGNX

CLMB

CMPO

CRDO

CRNC

CRSR

CSIQ

CSPI

CTSH

CWAN

CXDO

DAKT

DAVA

DCBO

DGII

DIOD

DJCO

DMRC

DOCN

DOMO

EBON

EPAM

ETWO

EVCM

EVLV

EXFY

FARO

FCUV

FLEX

GDYN

GRRR

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IDCC

INFA

INFY

INGM

INSG

IONQ

IPGP

ITRI

JAMF

Shares of broader tech companies are trading higher following President Trump's decision to implement a 90-day pause on reciprocal tariffs for all countries except China.

In the current session, Dolby Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) is trading at $70.85, after a 2.26% drop. Over the past month, the stock fell by 14.36%, and in the past year, by 15.99%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1744059618_0.png" alt="Past Year Chart" />

<h3>Comparing Dolby Laboratories P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Dolby Laboratories has a lower P/E than the aggregate P/E of 67.27 of the Software industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744059618_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Dolby Laboratories Inc's Price Over Earnings

Movie theater operator AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) is betting big on premium screens to add to its revenue over the <a href="https://www.benzinga.com/trading-ideas/movers/25/03/44562437/whats-going-on-with-amc-entertainment-stock-monday">next several years.</a>
The move comes with several of the top film franchises of all time having movies set for release.
What Happened: The <a href="https://www.benzinga.com/general/entertainment/24/12/42750888/top-anticipated-2025-movies-for-big-screen-success-and-stocks-investors-should-watch">2025 theatrical movie lineup </a>includes three Marvel films from Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) and plenty of other highly anticipated movies from franchises of old and new.
While 2025 could have a strong post-COVID-19 box office total, AMC has its sights set on 2025, 2026 and 2027.
The company recently announced it was adding 40 Dolby Cinema theaters through the end of 2027. The new additions will bring AMC's total number of Dolby premium screens to more than 200, as reported by <a href="https://www.cnbc.com/2025/03/31/amc-premium-screens-hollywood-movies.html">CNBC</a>.
"Premium moviegoing is defining the modern box office," Dolby Laboratories CEO Kevin Yeaman said.
Dolby Laboratories Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) is one of several premium screen formats and partners with AMC.
AMC also recently announced a partnership with CJ 4DPLEX for 40 4DX theaters and 25 SCREENX theaters to be opened across the U.S. and Europe beginning in the summer of 2025. This marks the first partnership between the two companies.
The premium format movie screens being added come ahead of a strong movie lineup that AMC CEO Adam Aron has been highlighting for more than a year. From 2025 to 2027, new films will be released from the Star Wars, Jurassic Park, Avatar, Marvel, DC Comics and Mission Impossible franchises.
Premium large format screens come with a higher ticket price for consumers and a way for AMC to add to its overall revenue. PLFs made up around 9.1% of the 2024 domestic box office, representing a total of $600 million split between multiple theater companies.
AMC has over 900 movie theaters and 10,000 screens worldwide as the world's largest movie theater company. The newest bets on premium format screens could add to the company's excitement for the coming box office lineup.
In <a href="https://www.benzinga.com/general/entertainment/25/02/43958798/amc-q4-earnings-revenue-beat-eps-in-line-attendance-up-20-shares-climb">the fourth quarter</a>, AMC reported attendance of 62.42 million, which was up 20.2% year-over-year. The company also reported its highest fourth-quarter food and beverage per person revenue in company history.
With higher attendance and more revenue from premium screens, along with increasing food and beverage revenue, the next three years could be key to the AMC turnaround story.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/05/39010959/amc-ceo-says-were-still-here-how-taylor-swift-popcorn-buckets-help-movie-theater-from-going">AMC CEO Says &#8216;We&#8217;re Still Here&#8217;: How Taylor Swift, Popcorn Buckets Help Movie Theater From Going &#8216;Kaplooey&#8217;</a>
AMC Post-COVID-19: For several years, Aron has discussed the <a href="https://www.benzinga.com/general/entertainment/24/04/38184776/amc-ceo-says-bankruptcy-is-inconceivable-as-shares-hit-52-week-lows-2025-2026-are-going-to-">post-COVID-19 recovery efforts</a> from AMC, which have included focusing on food and beverage and non-movie opportunities such as Taylor Swift concert films to offset less blockbuster movie releases.
A recent <a href="https://x.com/CEOAdam/status/1906823615737413781">tweet </a>from Aron mentioning the post-COVID-19 time period caught a reply of "the only CEO in the world still talking about covid!" from a social media user.
Aron felt the need to reply with "the facts" that people want to ignore.
"The industry-wide domestic box office in movie theatres was over $11 billion five years in a row pre-Covid. It was over $10 billion eleven years in a row pre-Covid," Aron said.
The CEO said the industry posted domestic box office of $8.8 billion in 2024, down over 20% from 2019 levels.
"When a high fixed cost industry like the movie theatre industry loses 20% of its revenue, its profits and cash balances plummet by far more."
Aron said the movie theater industry "has not fully recovered yet" and the recovery is taking longer than many expected or hoped.
"We are optimistic that a rising box office over the next year or two will be a great boon for AMC."
Aron also brushed off concerns about his salary in another <a href="https://x.com/CEOAdam/status/1907002331906077007">tweet</a>.
"I understand why you would be distraught if my salary was $23 million per year. Except that it isn't."
Aron said his salary is $1.5 million annually, as he has requested no raises. He is also paid cash bonuses related to company performance. The CEO said these amounts are less than one-third of his publicly reported total compensation, due to reporting of AMC share compensation.
"The bulk of my total compensation is in AMC stock."
Aron said he has not sold one share of AMC stock in more than three years. 
AMC Price Action: AMC stock is down 2.95% to $2.80 on Tuesday versus a 52-week trading range of $2.38 to $11.88. AMC stock is down 30.9% year-to-date in 2025.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44442150/meme-stock-meets-ai-how-amc-could-help-moviegoers-never-see-subtitles-again">Meme Stock Meets AI: How AMC Could Help Moviegoers Never See Subtitles Again</a></li>
</ul>
Photo: Shutterstock

Entertainment

Trading Ideas

AMC CEO Bets Big On Star Wars, Avatar, Jurassic Park, Marvel Franchises By Adding More Premium Screens

AMC Entertainment Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) shares are trading lower. The company on Monday announced a major expansion of Dolby Cinema at <a href="https://www.benzinga.com/pressreleases/25/03/n44560135/dolby-and-amc-entertainment-announce-major-expansion-of-dolby-cinema-at-amc-in-the-us-with-40-addi">AMC theaters in the United States</a>.
What Happened: AMC and Dolby Laboratories Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) announced an expanded partnership to add 40 additional Dolby Cinemas at AMC locations in the U.S. through 2027.
The expansion will bring AMC&#8217;s total Dolby Cinema theaters to over 200. The companies also agreed to extend their commitment to the existing Dolby Cinema network.
&#8220;For a decade, AMC and Dolby have provided moviegoers with incredible premium experiences &#8211; making the biggest blockbusters even bigger, brighter, louder, and more immersive,&#8221; said&nbsp;Adam Aron, chairman and CEO of AMC Entertainment. 
&#8220;The expansion of this partnership is a powerful demonstration of AMC&#8217;s ongoing commitment to deliver this premium experience – sought out by filmmakers, studio partners, and our guests – to even more of our theaters and AMC moviegoers around&nbsp;the United States.&#8221;
In addition to the new locations, AMC said it also selected Dolby Vision as its HDR offering of choice. The company noted that 49 of the top 50 movies over the past five years were shown in Dolby Cinema theaters.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44551992/ripples-legal-win-bitcoin-demand-robinhoods-banking-vision-and-gamestops-bitcoin-strategy-this-week-in-crypto">Ripple&#8217;s Legal Win, Bitcoin Demand, Robinhood&#8217;s Banking Vision, And Gamestop&#8217;s Bitcoin Strategy: This Week In Crypto</a>
When AMC reported <a href="https://www.benzinga.com/general/entertainment/25/02/43958798/amc-q4-earnings-revenue-beat-eps-in-line-attendance-up-20-shares-climb">fourth-quarter financial results</a> last quarter, the company noted that it planned to work on expanding its premium large format, extra-large format and special purpose screens in 2025.
Fourth-quarter attendance totaled 62.42 million, up 20.2% on a year-over-year basis. AMC said U.S. attendance came in at 42.96 million, up 21.1% year-over-year.
&#8220;As we look ahead to 2025 and beyond, we look forward to what we believe will be material growth in the industry-wide box office. To best benefit from such growth, we remain committed to continually improving the experience in our theatres for our guests,&#8221; Aron said last month.
AMC Price Action: <a href="http://benzinga.com/quote/amc">AMC shares</a> were down 2.13% at $2.82 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

What's Going On With AMC Entertainment Stock Monday?

New Interoperability Agreement Accelerates Wireless Audio Integration for Android and Linux A/V Platforms
WiSA Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WISA#NASDAQ">WISA</a>), soon to be doing business as Datavault&#xAE; AI, today announced a new interoperability license agreement with Dolby. This agreement allows Datavault AI to collaborate directly with system-on-chip (SoC) providers to integrate its patented WiSA E Express multichannel wireless audio software into Android and future Linux-based streaming A/V platforms.

WISA

WiSA Technologies Soon To Be Doing Business As Datavault AI, Signs Interoperability License Agreement With Dolby; Accelerating Wireless Audio Integration For Android And Linux A/V Platforms

Dolby Laboratories shares are trading higher after the company reported better-than-expected Q1 financial results.

Rosenblatt analyst Steven Frankel maintains Dolby Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) with a Buy and maintains $100 price target.

Rosenblatt Maintains Buy on Dolby Laboratories, Maintains $100 Price Target

Press Releases

General

Dolby Laboratories Announces Conference Call and Webcast for Q1 Fiscal 2025 Financial Results

Dividends

Dolby Laboratories Reports First Quarter 2025 Financial Results

Comcast and Dolby to Deliver First-Ever Super Bowl in Both Dolby Vision and Dolby Atmos

Relive the Revolution in Dolby as Purple Rain Returns Exclusively to Dolby Cinema

Dolby and General Motors Bring Dolby Atmos to Cadillac's Entire 2026 EV Lineup

Contracts

Dolby and AMC Entertainment announce major expansion of Dolby Cinema at AMC in the US, with 40 additional auditoriums to be added by the end of 2027

Dolby Laboratories Announces Conference Call and Webcast for Q2 Fiscal 2025 Financial Results

Dolby Laboratories Reports Second Quarter 2025 Financial Results

Dolby Laboratories President and CEO Kevin Yeaman to Host Fireside Chat at the William Blair 45th Annual Growth Stock Conference

TCL Brings Dolby Atmos FlexConnect to 2025 QD-Mini LED TVs

CMCSA

Comments

Dolby Laboratories

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL